These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23812862)

  • 1. Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection.
    Russo MW; Narang T; Eskind L; Hayes D; Casingal V; Purdum PP; Hanson JS; Ahrens W; Norton J; Bonkovsky H
    Dig Dis Sci; 2013 Oct; 58(10):3010-6. PubMed ID: 23812862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
    Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
    Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
    World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.
    Al-Hamoudi W; Mohamed H; Abaalkhail F; Kamel Y; Al-Masri N; Allam N; Alqahtani S; Al-Sofayan M; Khalaf H; Al-Sebayel M; Al-Jedai A; Abdo A
    Dig Dis Sci; 2011 Jun; 56(6):1848-52. PubMed ID: 21221800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
    Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.
    Miuma S; Ichikawa T; Miyaaki H; Haraguchi M; Tamada Y; Shibata H; Taura N; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
    J Interferon Cytokine Res; 2016 Jun; 36(6):358-66. PubMed ID: 27243278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report.
    Mishra P; DeVoss A; Pai R; Hart J; Jensen DM
    Dig Dis Sci; 2009 Jun; 54(6):1369-72. PubMed ID: 18770036
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.
    Eurich D; Bahra M; Berg T; Boas-Knoop S; Biermer M; Neuhaus R; Neuhaus P; Neumann U
    Exp Clin Transplant; 2011 Feb; 9(1):1-6. PubMed ID: 21605016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
    Sulkowski M; Pol S; Mallolas J; Fainboim H; Cooper C; Slim J; Rivero A; Mak C; Thompson S; Howe AY; Wenning L; Sklar P; Wahl J; Greaves W;
    Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
    Izumi N; Yokosuka O; Kawada N; Osaki Y; Yamamoto K; Sata M; Ishikawa H; Ueki T; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):501-10. PubMed ID: 24451151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation.
    Gordon FD; Kwo P; Ghalib R; Crippin J; Vargas HE; Brown KA; Schiano T; Chaudhri E; Pedicone LD; Brown RS
    J Clin Gastroenterol; 2012 Sep; 46(8):700-8. PubMed ID: 22739223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
    Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon.
    Schmidt SC; Bahra M; Bayraktar S; Berg T; Schmeding M; Pratschke J; Neuhaus P; Neumann U
    Dig Dis Sci; 2010 Jul; 55(7):2063-9. PubMed ID: 19798575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation.
    Ponziani FR; Annicchiarico EB; Siciliano M; D'Aversa F; Pompili M; Gasbarrini A
    World J Gastroenterol; 2013 Jun; 19(21):3255-62. PubMed ID: 23745027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.